Cel Besides DNA mutations, cancers harbor complex aberrations of the epigenetic landscape, which are reversible and amenable to pharmacologic intervention. Therapeutic targeting of chromatin regulators has shown great promise in first clinical studies, and this has triggered a massive effort to explore this machinery in academic and pharmaceutical research. Recently, the bromodomain and extraterminal domain (BET) containing protein 4 (BRD4), a reader of histone-acetyl marks, has emerged as a promising therapeutic target, and newly identified small-molecule BET inhibitors have shown impressive effects in preclinical cancer models. Unlike most established drug targets, BRD4 is typically not mutated or overexpressed in sensitive cell types, yet different cancer contexts show vast differences in their sensitivity to BET inhibition. This suggests that cancer cells can become “non-oncogene addicted” to BRD4. However, the mechanistic basis for this phenomenon remains elusive and so far no biomarker could be identified for predicting the sensitivity or resistance to BET inhibition. Moreover, preliminary results in an AML mouse model suggest that cells can rapidly become resistant to BRD4 inhibition, most likely through an epigenetic mechanism. This project will use an innovative approach combining proteomic profiling, advanced RNAi technologies and experimentally tractable mouse models of cancer to systematically identify and functionally characterize molecular determinants of sensitivity and resistance to BET inhibition. Advancing this mechanistic understanding will not only be critical for the further development of BET inhibitors in the clinic, but may reveal other key players that might be interesting as complementary or alternative target molecules. We believe that this study will contribute to a better understanding of epigenetic mechanisms in cancer and therapy resistance, which will be essential for further exploring this promising class of therapeutic targets. Dziedzina nauki natural sciencesbiological sciencesgeneticsDNAnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsnatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesclinical medicineoncologynatural sciencesbiological sciencesgeneticsepigenetics Program(-y) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Temat(-y) FP7-PEOPLE-2012-IEF - Marie-Curie Action: "Intra-European fellowships for career development" Zaproszenie do składania wniosków FP7-PEOPLE-2012-IEF Zobacz inne projekty w ramach tego zaproszenia System finansowania MC-IEF - Intra-European Fellowships (IEF) Koordynator FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH Wkład UE € 186 783,60 Adres CAMPUS-VIENNA-BIOCENTER 1 1030 Wien Austria Zobacz na mapie Region Ostösterreich Wien Wien Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Kontakt administracyjny Tanja Winkler (Mrs.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych